Quantitative analysis of receptor allosterism and its implication for drug discovery

Expert Opinion on Drug Discovery

Volumn 10, Issue 7, 2015, Pages 763-780

  Zhang, Rumin ^a   Kavana, Michael ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Agonism; Allosteric two state model; Bitopic or dualsteric agonist; Full agonist; G protein couple receptor; Global curve fitting; Monte Carlo simulation; Negative allosteric modulators; Operational model; Orthosterism; Partial agonist; Positive allosteric modulator; Receptor allosterism; Silent allosteric modulator; supremacy

Indexed keywords

G PROTEIN COUPLED RECEPTOR; LIGAND;

AGONIST; ALLOSTERISM; BINDING KINETICS; DRUG DESIGN; DRUG RESEARCH; DRUG SCREENING; HUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RECEPTOR AFFINITY; REVIEW; BINDING SITE; BIOLOGICAL MODEL; DRUG DEVELOPMENT; DRUG EFFECTS; METABOLISM; PROCEDURES; STRUCTURE ACTIVITY RELATION;

ALLOSTERIC REGULATION; ALLOSTERIC SITE; DRUG DESIGN; DRUG DISCOVERY; HUMANS; MODELS, BIOLOGICAL; RECEPTORS, G-PROTEIN-COUPLED; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84932115371     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2015.1041498     Document Type: Review

References (72)

1. Rees S, Morrow D, Kenakin T. GPCR drug discovery through the exploitation of allosteric drug binding sites. Receptors Channels 2002;8(5-6): 261-8
2. Bjarnadottir TK, Gloriam DE, Hellstrand SH, et al. Comprehensive repertoire and phylogenetic analysis of the G protein-coupled receptors in human and mouse. Genomics 2006;88(3):263-73
3. Overington JP, Al-Lazikani B, Hopkins AL. How many drug targets are there? Nat Rev 2006;5(12):993-6
4. Kruse AC, Kobilka BK, Gautam D, et al. Muscarinic acetylcholine receptors: novel opportunities for drug development. Nat Rev 2014;13(7):549-60
5. Manglik A, Kobilka B. The role of protein dynamics in GPCR function: insights from the beta2AR and rhodopsin. Cur Opin Cell Biol 2014;27:136-43
6. Ferre S, Casado V, Devi LA, et al. G protein-coupled receptor oligomerization revisited: functional and pharmacological perspectives. Pharmacol Rev 2014;66(2):413-34
7. Kang DS, Tian X, Benovic JL. Role of beta-arrestins and arrestin domaincontaining proteins in G protein-coupled receptor trafficking. Cur Opin Cell Biol 2014;27:63-71
8. Kenakin T, Williams M. Defining and characterizing drug/compound function. Biochem Pharmacol 2014;87(1):40-63
9. Costa T, Herz A. Antagonists with negative intrinsic activity at delta opioid receptors coupled to GTP-binding proteins. Proc Natl Acad Sci USA 1989;86(19):7321-5
10. Milligan G. Constitutive activity and inverse agonists of G protein-coupled receptors: a current perspective. Mol Pharmacol 2003;64(6):1271-6
11. Lane JR, Sexton PM, Christopoulos A. Bridging the gap: bitopic ligands of G-protein-coupled receptors. Trends Pharmacol Sci 2013;34(1):59-66
12. Mohr K, Schmitz J, Schrage R, et al. Molecular alliance-from orthosteric and allosteric ligands to dualsteric/bitopic agonists at G protein coupled receptors. Angew Chem Int Ed Engl 2013;52(2):508-16
13. Valant C, Robert Lane J, Sexton PM, et al. The best of both worlds? Bitopic orthosteric/allosteric ligands of g proteincoupled receptors. Annu Rev Pharmacol Toxicol 2012;52:153-78
14. Christopoulos A, Changeux JP, Catterall WA, et al. International Union of Basic and Clinical Pharmacology. XC. multisite pharmacology: recommendations for the nomenclature of receptor allosterism and allosteric ligands. Pharmacol Rev 2014;66(4):918-47
15. Christopoulos A, Kenakin T. G proteincoupled receptor allosterism and complexing. Pharmacol Rev 2002;54(2):323-74
16. Monod J, Changeux JP, Jacob F. Allosteric proteins and cellular control systems. J Mol Biol 1963;6:306-29
17. Monod J, Jacob F. General conclusions: teleonomic mechanisms in cellular metabolism, growth and differentiation. Cold Spring Harbor Symp Quant Biol 1961;26:389-401
18. Monod J, Wyman J, Changeux JP. On the Nature of Allosteric Transitions: a Plausible Model. J Mol Biol 1965;12:88-118
19. Changeux JP. Allosteric receptors: from electric organ to cognition. Annu Rev Pharmacol Toxicol 2010;50:1-38
20. van der Westhuizen ET, Valant C, Sexton PM, et al. Endogenous allosteric modulators of G protein-coupled receptors. J Pharmacol Exp Ther 2015;353(2):246-60
21. Burford NT, Clark MJ, Wehrman TS, et al. Discovery of positive allosteric modulators and silent allosteric modulators of the mu-opioid receptor. Proc Natl Acad Sci USA 2013;110(26):10830-5
22. Schann S, Mayer S, Franchet C, et al. Chemical switch of a metabotropic glutamate receptor 2 silent allosteric modulator into dual metabotropic glutamate receptor 2/3 negative/positive allosteric modulators. J Med Chem 2010;53(24):8775-9
23. Del Castillo J, Katz B. Interaction at end-plate receptors between different choline derivatives. Proc R Soc Lond B Biol Sci 1957;146(924):369-81
24. Hall DA. Modeling the functional effects of allosteric modulators at pharmacological receptors: an extension of the two-state model of receptor activation. Mol Pharmacol 2000;58(6):1412-23
25. Hall DA. Application of receptor theory to allosteric modulation of receptors. Prog Mol Biol Transl Sci 2013;115:217-90
26. Black JW, Leff P. Operational models of pharmacological agonism. Proc R Soc Lond B Biol Sci 1983;220(1219):141-62
27. Black JW, Leff P, Shankley NP, et al. An operational model of pharmacological agonism: the effect of E/[A] curve shape on agonist dissociation constant estimation. Br J Pharmacol 1985;84(2):561-71
28. Ehlert FJ. Analysis of allosterism in functional assays. J Pharmacol Exp Ther 2005;315(2):740-54
29. Kenakin T. New concepts in drug discovery: collateral efficacy and permissive antagonism. Nat Rev 2005;4(11):919-27
30. Leach K, Sexton PM, Christopoulos A. Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology. Trends Pharmacol Sci 2007;28(8):382-9
31. Price MR, Baillie GL, Thomas A, et al. Allosteric modulation of the cannabinoid CB1 receptor. Mol Pharmacol 2005;68(5):1484-95
32. Slack RJ, Hall DA. Development of operational models of receptor activation including constitutive receptor activity and their use to determine the efficacy of the chemokine CCL17 at the CC chemokine receptor CCR4. Br J Pharmacol 2012;166(6):1774-92
33. Stephenson RP. A modification of receptor theory. Br J Pharmacol Chemother 1956;11(4):379-93
34. Colquhoun D. Affinity, efficacy and receptor classification: is the classical theory still useful? In: Black JW, Jenkinson DH, Gerskowitch VP, Alan R, editors. Perspectives on hormone receptor classification. Liss Inc; New York: 1987. p. 103-14
35. Colquhoun D. Binding, gating, affinity and efficacy: the interpretation of structure-activity relationships for agonists and of the effects of mutating receptors. Br J Pharmacol 1998;125(5):924-47
36. Roche D, Gil D, Giraldo J. Mechanistic analysis of the function of agonists and allosteric modulators: reconciling two-state and operational models. Br J Pharmacol 2013;169(6): 1189-202
37. Tsai CJ, Nussinov R. A unified view of "how allostery works". PLoS Comput Biol 2014;10(2): e1003394
38. Colquhoun D. The quantitative analysis of drug-receptor interactions: a short history. Trends Pharmacol Sci 2006;27(3):149-57
39. Arunlakshana O, Schild HO. Some quantitative uses of drug antagonists. Br J Pharmacol and chemotherapy 1959;14(1):48-58
40. Paton WD, Rang HP. The Uptake of Atropine and Related Drugs by Intestinal Smooth Muscle of the Guinea-Pig in Relation to Acetylcholine Receptors. Proc R Soc Lond B Biol Sci 1965;163:1-44
41. Burzomato V, Beato M, Groot-Kormelink PJ, et al. Single-channel behavior of heteromeric alpha1beta glycine receptors: an attempt to detect a conformational change before the channel opens. J Neurosci 2004;24(48):10924-40
42. Roche D, Gil D, Giraldo J. Multiple active receptor conformation, agonist efficacy and maximum effect of the system: the conformation-based operational model of agonism. Drug Discov Today 2013;18(7-8):365-71
43. Keov P, Sexton PM, Christopoulos A. Allosteric modulation of G proteincoupled receptors: a pharmacological perspective. Neuropharmacology 2011;60(1):24-35
44. Leach K, Loiacono RE, Felder CC, et al. Molecular mechanisms of action and in vivo validation of an M4 muscarinic acetylcholine receptor allosteric modulator with potential antipsychotic properties. Neuropsychopharmacology 2010;35(4):855-69
45. Siddiquee K, Hampton J, McAnally D, et al. The apelin receptor inhibits the angiotensin II type 1 receptor via allosteric trans-inhibition. Br J Pharmacol 2012;168(5):1104-17
46. Smith NJ, Ward RJ, Stoddart LA, et al. Extracellular loop 2 of the free fatty acid receptor 2 mediates allosterism of a phenylacetamide ago-allosteric modulator. Mol Pharmacol 2011;80(1):163-73
47. Yin S, Noetzel MJ, Johnson KA, et al. Selective actions of novel allosteric modulators reveal functional heteromers of metabotropic glutamate receptors in the CNS. J Neurosci 2014;34(1):79-94
48. Billas I, Moras D. Allosteric controls of nuclear receptor function in the regulation of transcription. J Mol Biol 2013;425(13):2317-29
49. Kenakin T, Watson C, Muniz-Medina V, et al. A simple method for quantifying functional selectivity and agonist bias. ACS Chem Neurosci 2012;3(3):193-203
50. Kenakin TP. Biased signalling and allosteric machines: new vistas and challenges for drug discovery. Br J Pharmacol 2012;165(6):1659-69
51. Schwartz TW, Holst B. Allosteric enhancers, allosteric agonists and agoallosteric modulators: where do they bind and how do they act? Trends Pharmacol Sci 2007;28(8):366-73
52. Noetzel MJ, Rook JM, Vinson PN, et al. Functional impact of allosteric agonist activity of selective positive allosteric modulators of metabotropic glutamate receptor subtype 5 in regulating central nervous system function. Mol Pharmacol 2011;81(2):120-33
53. Kenakin T. Ligand detection in the allosteric world. J Biomolec screen 2010;15(2):119-30
54. Giraldo J. Operational models of allosteric modulation: caution is needed. Trends Pharmacol Sci 2015;36(1):1-2
55. Furchgott RF. The use of betahaloalkylamines in the differentiation of receptors and in the determination of dissociation constants of receptor-agonist complexes. In: Harper NJ, editor. Advances in Drug Research. Academic Press; New York: 1966. p. 21-55
56. Kenakin TP. The relative contribution of affinity and efficacy to agonist activity: organ selectivity of noradrenaline and oxymetazoline with reference to the classification of drug receptors. Br J Pharmacol 1984;81(1):131-41
57. Halls ML. Constitutive formation of an RXFP1-signalosome: a novel paradigm in GPCR function and regulation. Br J Pharmacol 2012;165(6):1644-58
58. Teitler M, Herrick-Davis K, Purohit A. Constitutive activity of G-protein coupled receptors: emphasis on serotonin receptors. Curr Top Med Chem 2002;2(6):529-38
59. Copeland RA. The dynamics of drugtarget interactions: drug-target residence time and its impact on efficacy and safety. Expert Opin Drug Discov 2010;5(4):305-10
60. Guo D, Hillger JM, AP IJ, et al. Drug-target residence time-a case for G protein-coupled receptors. Med Res Rev 2014;34(4):856-92
61. Swinney DC, Beavis P, Chuang KT, et al. A study of the molecular mechanism of binding kinetics and long residence times of human CCR5 receptor small molecule allosteric ligands. Br J Pharmacol 2014;171(14): 3364-75
62. Pitcher JA, Freedman NJ, Lefkowitz RJ. G protein-coupled receptor kinases. Ann Rev Biochem 1998;67:653-92
63. Corriden R, Kilpatrick LE, Kellam B, et al. Kinetic analysis of antagonistoccupied adenosine-A3 receptors within membrane microdomains of individual cells provides evidence of receptor dimerization and allosterism. Faseb J 2014;28(10):4211-22
64. Hill SJ, May LT, Kellam B, et al. Allosteric interactions at adenosine A(1) and A(3) receptors: new insights into the role of small molecules and receptor dimerization. Br J Pharmacol 2014;171(5):1102-13
65. May LT, Bridge LJ, Stoddart LA, et al. Allosteric interactions across native adenosine-A3 receptor homodimers: quantification using single-cell ligandbinding kinetics. Faseb J 2011;25(10):3465-76
66. Adamson RJ, Watts A. Kinetics of the early events of GPCR signalling. FEBS Lett 2014;588(24):4701-7
67. Ahles A, Rodewald F, Rochais F, et al. Interhelical interaction and receptor phosphorylation regulate the activation kinetics of different human beta1-adrenoceptor variants. J Biol Chem 2015;290(3):1760-9
68. Fichter KM, Flajolet M, Greengard P, et al. Kinetics of G-protein-coupled receptor endosomal trafficking pathways revealed by single quantum dots. Proc Natl Acad Sci USA 2010;107(43):18658-63
69. Lambert NA, Johnston CA, Cappell SD, et al. Regulators of G-protein signaling accelerate GPCR signaling kinetics and govern sensitivity solely by accelerating GTPase activity. Proc Natl Acad Sci USA 2010;107(15):7066-71
70. Lill Y, Martinez KL, Lill MA, et al. Kinetics of the initial steps of G proteincoupled receptor-mediated cellular signaling revealed by single-molecule imaging. ChemPhysChem 2005;6(8):1633-40
71. Vilardaga JP. Theme and variations on kinetics of GPCR activation/deactivation. J Recept Signal Transduct Res 2010;30(5):304-12
72. Vilardaga JP, Romero G, Feinstein TN, et al. Kinetics and dynamics in the G protein-coupled receptor signaling cascade. Methods Enzymol 2013;522:337-63